DE-GEMPHARMATECH
25.4.2022 14:32:08 CEST | Business Wire | Press release
GemPharmatech LLC is pleased to announce that on April 25, 2022, its parent company, GemPharmatech Co., Ltd., went public on the STAR MARKET of the Shanghai Stock Exchange under the stock code 688046. The initial offering included 50,000,000 ordinary shares at a public offering price of￥22.53 ($3.51) per share.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220425005235/en/
GemPharmatech, established on December 29, 2017, is a high-tech enterprise specializing in the research and development of laboratory animal models, production, technical services, and upstream and downstream industry expansion. In order to meet the rapid development needs of biomedical research and new drug development, the company has constructed more than 20,000 commercial mouse models with independent intellectual property rights, becoming the world's largest collection of mouse strains. These models promote research and development breakthroughs in the fields of gene function identification, disease mechanism analysis, drug target discovery, drug efficacy screening and verification, and provides a solution to the bottleneck of animal model technology. GemPharmatech has established subsidiaries in Beijing, Foshan, Chengdu, Changzhou, Guangzhou, and Shanghai, as well as a US subsidiary, GemPharmatech LLC. The company’s facilities include 30,000+ square meters of SPF-level facilities.
Models That Defy the Impossible
According to Dr. Xiang Gao, founder and Chairman of GemPharmatech Co. Ltd., “GemPharmatech will take this issuance and listing as an opportunity to keep up with the frontier trends of life science and new drug development, adhere to an R&D-driven strategy, continuously optimize the laboratory animal construct strategy and genetic engineering technology, and improve our preclinical service capabilities.”
“GemPharmatech will use the funds raised by the IPO for investment in key projects such as launching a germ-free mouse platform, and to further expand global market share and influence,” says US CEO Dr. Mark Moore. “The company is committed to providing the best service to our customers, promoting the development of the biopharmaceutical industry, and repaying the society, employees and investors through excellent business performance.”
About GemPharmatech
GemPharmatech is a leading provider of animal models and services to the global preclinical R&D community. We specialize in developing animal models using cutting edge gene-editing technologies with a large collection of cKO/KO (conditional knockout/knockout) mice, humanized mice, immunodeficient mice, and germ-free mice. GemPharmatech provides an expansive array of preclinical services, including mouse model customization, pharmacology services such as drug efficacy testing, and customized breeding. The company has developed one of the world's largest collections of mouse models to enable scientific innovation and accelerate drug development. Learn more at gempharmatech.us.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220425005235/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
VELOCIFERO Takes Action Against Counterfeiting in China13.11.2026 17:32:00 CET | Press release
White s.r.o., exclusive owner of the VELOCIFERO brand, takes action in China to protect its intellectual property rights. Initial measures in Chongqing and Taizhou have already resulted in the seizure of vehicles alleged to be counterfeit. VELOCIFERO is taking action against counterfeiting in China. White s.r.o., the exclusive owner of the VELOCIFERO brand and its related intellectual property rights, has launched decisive measures to protect its creative and industrial assets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261113797570/en/ Photo courtesy of White s.r.o. “Vehicle sealed in Chongqing as part of actions undertaken to protect VELOCIFERO’s intellectual property rights.” The matter originated in June 2026 when, according to the company’s complaint, computers were removed from the technical office of Taizhou Siweiluo, the company appointed to manufacture VELOCIFERO products. White s.r.o. subsequently became aware
LangChain Raises $300M to Enable Every Company to Own Their Intelligence13.11.2026 16:53:00 CET | Press release
CapitalG leads Series C funding round at a $3B valuation to advance LangChain's agent engineering platform LangChain today announced it has raised $300 million in new funding at a $3 billion valuation, bringing total funding to date to $460 million. The round was led by existing investor CapitalG, with significant participation from new investors GIC and DFJ Growth and existing investors IVP and Sapphire Ventures. LangChain is advancing its mission to help every company own its intelligence. As agents transform the economy, companies are building domain-specific agents differentiated by their knowledge, data, and user experience. These agents will power new products and transform internal company operations, creating lasting competitive advantages for the companies that control them. "Agents are going to transform how companies operate and the products they deliver. The companies that control these systems will build lasting competitive advantages," said Harrison Chase, Co-Founder and
Kinaxis Named a Leader in Five 2026 IDC MarketScapes for Worldwide Supply Chain Planning13.11.2026 13:00:00 CET | Press release
Maestro delivers concurrent planning on a single platform across discrete, process, consumer packaged goods and life sciences Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain planning and orchestration, today announced it has been named a Leader in five 2026 IDC MarketScape vendor assessments for worldwide supply chain planning. The recognition spans the overall market and four industries - discrete industries, process industries, consumer packaged goods and life sciences industries - all served by a single platform, Kinaxis Maestro®, the company's AI-powered supply chain orchestration platform. "Supply chain leaders don't need a better forecast once a month. They need to know what changed this morning, what it means across the business, and what to do about it," said Andrew Bell, Chief Product Officer of Kinaxis. "I believe being named a Leader across five IDC MarketScape vendor assessments, in industries that plan in very different ways, shows that a single concurr
SBC Medical Announces Capital and Business Alliance with NeuroBrain Dynamics to Advance Clinic Profitability Through Medical AI13.11.2026 12:30:00 CET | Press release
Companies to co-develop six medical AI solutions targeting revenue expansion and cost reduction; SBC Medical secures priority sales rights in Japan and South Korea and targets B2B expansion across Asia SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“The Company” or “SBC Medical”), a Medical Services Organization (MSO) providing management support across a wide range of healthcare fields, today announced a strategic capital and business alliance agreement with NeuroBrain Dynamics Inc. (“NBD”), a Taipei-based company dedicated to enterprise generative AI solutions. As part of the agreement executed on November 13, 2026, SBC Medical has made a minority equity investment in NBD. Through this alliance, SBC Medical plans to introduce two complementary suites of generative AI solutions across its network of 287 clinics in Japan and overseas*: “revenue-growth AI,” to elevate average revenue per visit and customer retention through personalized customer guidance, and “cost-reduction AI,
SBC Medical Group Holdings Reports Third Quarter 2026 Financial Results13.11.2026 12:30:00 CET | Press release
Revenue Up 35%, Net Income Attributable to SBC Medical Up 22%, and Adjusted EBITDA1 Up 66% Year-over-Year; Net Income Margin of 27% and Adjusted EBITDA Margin of 47% — Previously Announced Service Fee Revisions and New Clinic Openings Contribute to Revenue Growth and Operating Margin Improvement SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a Medical Services Organization (MSO) providing management support across a wide range of healthcare fields to medical institutions in Japan and abroad, today announced its consolidated financial results for the third quarter of fiscal year 2026 (the three months ended September 30, 2026) and the three cumulative quarters of fiscal year 2026 (the nine months ended September 30, 2026). Third Quarter 2026 Financial Highlights Total revenues were $59 million, up 35% year-over-year. Income from operations was $26 million, up 66% year-over-year, with an operating margin of 45%. Net income attributable to SBC Medi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom